Scarica l'app Stockscreener
5.39
2.93%
0.17
Dopo l'orario di chiusura:
5.39
Precedente Chiudi:
$5.22
Aprire:
$5.99
Volume 24 ore:
10.05M
Relative Volume:
10.15
Capitalizzazione di mercato:
$348.72M
Reddito:
$500
Utile/perdita netta:
$-56.02M
Rapporto P/E:
-3.9027
EPS:
-1.3811
Flusso di cassa netto:
$-45.49M
1 W Prestazione:
+4.13%
1M Prestazione:
-8.78%
6M Prestazione:
-26.40%
1 anno Prestazione:
+270.56%
Intervallo 1D:
$5.29
$6.89
Intervallo di 1 settimana:
$4.81
$6.89
Portata 52W:
$1.42
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.39 | 337.72M | 500 | -56.02M | -45.49M | -1.3811 |
VRTX
Vertex Pharmaceuticals Inc
|
433.27 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.76 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.03 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.93 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.57 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Iniziato | Leerink Partners | Outperform |
| 2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Iniziato | Needham | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Immuneering reports 17.3-month survival in pancreatic cancer trial - Investing.com
Immuneering stock jumps on pancreatic cancer trial data By Investing.com - Investing.com Nigeria
Immuneering stock jumps on pancreatic cancer trial data - Investing.com
Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026 - Quiver Quantitative
Pancreatic cancer trial of Immuneering drug hits 17.3-month median survival - Stock Titan
Immuneering Corp stock (US45255L1089): clinical updates keep biotech investors watching - AD HOC NEWS
Immuneering stock (US45255L1089): Insider buying puts the biotech back in focus - AD HOC NEWS
Immuneering Corp Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Immuneering Corporation Reports Q1 2026 Financial Results and Announces Positive Phase 2a Pancreatic Cancer Trial Data - Minichart
Immuneering Hikes on Q1 Figures - Baystreet.ca
Immuneering to present pancreatic cancer trial data at ASCO - Investing.com
Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary - TradingView
Immuneering (IMRX) advances atebimetinib into MAPKeeper 301 Phase 3 - Stock Titan
Immuneering reports Q1 2026 net loss $13.5M, $198.6M cash runway into 2029 - TradingView
Pancreatic data and cash runway into 2029 at Immuneering (NASDAQ: IMRX) - Stock Titan
Pancreatic cancer patient gets 27 months progression-free on Immuneering drug - Stock Titan
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Immuneering Corp stock (US45255L1089): Q4 beat and 174% YTD surge - AD HOC NEWS
TradingKey - TradingKey
The one question every Immuneering Corporation (IMRX) investor should ask (Smart Money Flows) 2026-05-11Crowd Risk Alerts - newser.com
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors - TipRanks
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely - Yahoo Finance
Insider Buyers At Immuneering Sitting On US$361k Profit - Sahm
Immuneering Corp (IMRX) Stock Price, Quote, News & History - Benzinga
Immuneering brings 55-patient pancreatic survival update to ASCO oral - Stock Titan
Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification - Stock Titan
Immuneering (IMRX) Reveals Promising Genetic Data at Upcoming AA - GuruFocus
Immuneering presents genetic data on atebimetinib resistance - Investing.com
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - The Manila Times
In 123 patients, Immuneering's cancer drug showed rare resistance signals - Stock Titan
Immuneering Corporation (IMRX) Stock: Technical Strength Check (Risk Aversion) 2026-04-18Hot Stocks - Newser
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears - Yahoo Finance
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Needham healthcare fireside chat adds Immuneering CEO on April 13 - Stock Titan
Immuneering CorporationClass A Common Stock (NQ: IMRX - The Chronicle-Journal
Immuneering Corp Stock: Precision Oncology Innovator with Deep Pipeline Potential for North American - AD HOC NEWS
Bull Bear: Can Immuneering Corporation scale operations efficiently2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Immuneering Corp Stock (ISIN: US45255L1089) Faces Short-Term Pressure Amid Clinical Momentum and Ana - AD HOC NEWS
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - The Manila Times
Immuneering Corp (IMRX) CPO acquires shares through employee stock plan - Stock Titan
New MEK approach in 64 cancer patients shows fewer resistance mutations - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - AOL.com
Immuneering (IMRX) to Release Earnings on Thursday - MarketBeat
Piper Sandler cuts Immuneering stock price target on launch timing - Investing.com
Why Immuneering Corporation stock could outperform in 2026Earnings Growth Report & Community Supported Trade Ideas - Naître et grandir
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen - MarketBeat
Immuneering Corporation Q4 & Full Year 2025 Earnings: EPS Beats -$0.18 Estimate - Bayelsa Watch
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Immuneering 2025 10-K: $0 Revenue, $(1.27) EPS and $(56.0)M Net Loss - TradingView
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immuneering Corp Azioni (IMRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
| Feinberg Peter | Director |
Sep 30 '25 |
Buy |
7.03 |
7,500 |
52,730 |
149,266 |
| Feinberg Peter | Director |
Sep 29 '25 |
Buy |
7.18 |
5,000 |
35,900 |
141,766 |
5.06%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):